Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<scp>GIMEMA MDS</scp>0306 <scp>T</scp>rial)

Abstract

Deferasirox therapy in transfusion-dependent patients with MDS was moderately well tolerated and effectively lowered serum ferritin levels. Positive hematological responses were observed, and a subset of patients achieved transfusion independence.